{"id":"9mw0813","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to PD-L1 on tumor cells and immune cells, 9MW0813 prevents the engagement of PD-L1 with its receptors on T cells, thereby releasing the brake on T-cell activation and proliferation. This allows the immune system to mount a more robust anti-tumor response. The drug is designed to restore anti-tumor immunity in patients with PD-L1-expressing malignancies.","oneSentence":"9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:58:19.453Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05324774","phase":"PHASE3","title":"Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-02-28","conditions":"Diabetic Macular Edema","enrollment":346},{"nctId":"NCT05324592","phase":"PHASE1","title":"Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2021-02-26","conditions":"Diabetic Macular Edema","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"9MW0813","genericName":"9MW0813","companyName":"Mabwell (Shanghai) Bioscience Co., Ltd.","companyId":"mabwell-shanghai-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}